Neoplasms, Hormone-Dependent
"Neoplasms, Hormone-Dependent" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
Concept/Terms
Neoplasms, Hormone-Dependent- Neoplasms, Hormone-Dependent
- Neoplasms, Hormone Dependent
- Hormone-Dependent Neoplasms
- Hormone Dependent Neoplasms
- Hormone-Dependent Neoplasm
- Neoplasm, Hormone-Dependent
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Hormone-Dependent".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Hormone-Dependent".
This graph shows the total number of publications written about "Neoplasms, Hormone-Dependent" by people in Harvard Catalyst Profiles by year, and whether "Neoplasms, Hormone-Dependent" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 4 | 1 | 5 |
| 1996 | 3 | 1 | 4 |
| 1997 | 2 | 1 | 3 |
| 1998 | 4 | 2 | 6 |
| 1999 | 5 | 1 | 6 |
| 2000 | 5 | 1 | 6 |
| 2001 | 3 | 3 | 6 |
| 2002 | 6 | 4 | 10 |
| 2003 | 5 | 3 | 8 |
| 2004 | 7 | 3 | 10 |
| 2005 | 5 | 4 | 9 |
| 2006 | 11 | 8 | 19 |
| 2007 | 7 | 7 | 14 |
| 2008 | 20 | 10 | 30 |
| 2009 | 8 | 6 | 14 |
| 2010 | 6 | 2 | 8 |
| 2011 | 8 | 3 | 11 |
| 2012 | 18 | 2 | 20 |
| 2013 | 6 | 3 | 9 |
| 2014 | 8 | 4 | 12 |
| 2015 | 2 | 3 | 5 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 1 | 4 |
| 2020 | 3 | 0 | 3 |
| 2021 | 2 | 0 | 2 |
Below are the most recent publications written about "Neoplasms, Hormone-Dependent" by people in Profiles.
-
Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer. Clin Cancer Res. 2021 05 15; 27(10):2706-2711.
-
Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. 2021 09; 24(3):623-637.
-
Association between selenium intake and breast cancer risk: results from the Women's Health Initiative. Breast Cancer Res Treat. 2020 Aug; 183(1):217-226.
-
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. BMC Cancer. 2020 Apr 23; 20(1):347.
-
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020 02 18; 22(1):22.
-
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020 02 03; 22(1):16.
-
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. J Clin Oncol. 2019 02 10; 37(5):386-395.
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
-
Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature. Clin Breast Cancer. 2019 02; 19(1):e12-e19.
-
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clin Cancer Res. 2018 10 01; 24(19):4662-4671.